Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.59 |
| ▸ | CAMK2D | Q13557 | 6/20 | 0.58 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | BCR | P11274 | 2/20 | 0.56 |
| ▸ | PRKCA | P17252 | 2/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | PRKACG | P22612 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246773 | 0.88 | NUDT1 (0.61) | EIF2AK2CAMK2DABL1BCRPRKCA | |
| SCHEMBL14123853 | 0.87 | CDK1 (0.64) | EIF2AK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL3623722 | 0.85 | EIF2AK2 (0.55) | EIF2AK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL3620128 | 0.83 | CDK9 (0.64) | EIF2AK2ABL1BCRPRKCAPRKCD | |
| SCHEMBL13051120 | 0.81 | ABL1 (0.58) | EIF2AK2CAMK2DABL1BCRPRKCA | |
| SCHEMBL12723013 | 0.81 | ABL1 (0.58) | EIF2AK2CAMK2DABL1BCRPRKCA | |
| SCHEMBL3617951 | 0.80 | CDK1 (0.54) | EIF2AK2CDK2CDK4SYKEGFR | |
| SCHEMBL3599515 | 0.79 | ABL1 (0.65) | EIF2AK2CAMK2DABL1BCRPRKCA | |
| SCHEMBL3251717 | 0.79 | CDK1 (0.76) | EIF2AK2CAMK2DABL1BCRPRKCA | |
| SCHEMBL3618907 | 0.79 | BRD4 (0.48) | EIF2AK2PRKCAPRKCDCDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| EP-2094681-A1 | INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008079918-A1 | INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079918-A1 | INDOL-4-YL-PYRIMIDINYL-2-YL-AMINE DERIVATIVES AND USE THEREOF AS CYCLIN DEPENDANT KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | EIF2AK2 2174/4885CAMK2D 4474/4885ABL1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.